ViaCyte to Present at Investor, Partnering, and Scientific Conferences in October

SAN DIEGO, Sept. 27, 2018 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced upcoming company presentations at the Cell and Gene Meeting on the Mesa and the BIO Investor Forum.  In addition, a scientific presentation will be given at the Frontiers in Organoid Medicine Symposium.  ViaCyte is developing novel stem cell-derived islet replacement therapies for insulin-requiring diabetes.  ViaCyte's product candidates have the potential to provide a functional cure for patients with type 1 diabetes as well as an important therapy for patients with type 2 diabetes that depend on insulin to help control their disease.

"In the past year, we have made important progress with both our clinical stage product candidates, bringing us closer to our goal of introducing the first stem cell-derived islet replacement therapies for insulin-requiring diabetes.  We have also established industry-leading collaborations to continue innovative research for the field," said Paul Laikind, PhD, President and CEO of ViaCyte.  "We recently announced a collaboration with CRISPR Therapeutics to discover, develop, and commercialize gene-edited allogeneic stem cell therapies for the treatment of diabetes. We have also strengthened our collaboration with research partner and investor, W.L. Gore & Associates and announced positive data showing improved engraftment and function of the PEC-Encap product candidate in a clinically relevant non-clinical model.  If the progress continues as expected, we plan to resume enrollment in the STEP ONE trial for PEC-Encap as early as the first half of 2019."

Dr. Laikind will give the company presentation here:

Dr. Laikind will also participate on a panel at BIO Investor Forum, called "Learning from Translational Research Success to Attract Investment," which will take place October 17 at 9:45 am PT.

Kevin D'Amour, Ph.D. Vice President, Research and Chief Scientific Officer, will be providing a scientific presentation here:

About ViaCyte

ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications.  ViaCyte's product candidates are based on the derivation of pancreatic progenitor cells from stem cells, which are then implanted in durable and retrievable cell delivery devices.  Once implanted and matured, these cells are designed to secrete insulin and other pancreatic hormones in response to blood glucose levels.  ViaCyte has two product candidates in clinical-stage development.  The PEC-Direct™ product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes.  The PEC-Encap™ (also known as VC-01) product candidate delivers the same pancreatic progenitor cells in an immunoprotective device and is being developed for all patients with diabetes, type 1 and type 2, who use insulin.  ViaCyte is also seeking to develop immune-evasive 'universal donor' stem cell lines, from its proprietary CyT49 cell line, which have the potential to further broaden the availability of cell therapy for diabetes and other potential indications.  ViaCyte is headquartered in San Diego, California.  ViaCyte is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. For more information on ViaCyte, please visit www.viacyte.com and connect with ViaCyte on Twitter and Facebook.

SOURCE ViaCyte, Inc.

Related Links

http://www.viacyte.com